Sibutramine lost and found

Eating and Weight Disorders

Volumn 7, Issue 3, 2002, Pages 161-167

  Bosello, O ^a   Carruba, M O ^b   Ferrannini, E ^c   Rotella, C M ^d  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Adverse events; Drug treatment; Obesity; Safety; Sibutramine

Indexed keywords

ANOREXIGENIC AGENT; ANTIDEPRESSANT AGENT; CYCLOBUTANE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE;

DRUG EFFECT; FEMALE; HUMAN; ITALY; MORTALITY; OBESITY; QUALITY OF LIFE; REVIEW; WEIGHT REDUCTION;

ANTIDEPRESSIVE AGENTS; APPETITE DEPRESSANTS; CYCLOBUTANES; FEMALE; HUMANS; ITALY; OBESITY; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS; WEIGHT LOSS;

EID: 0036726645     PISSN: 11244909     EISSN: 15901262     Source Type: Journal    
DOI: 10.1007/BF03327453     Document Type: Article

References (53)

1. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Geneva, Switzerland: Report of a WHO Consultation; Technical Report Series, 894, 2000.
2. Istituto Nazionale di Statistica (ISTAT): Indagine sullo stato di salute e ricorso ai servizi sanitari. Fattori di rischio e tutela della salute, Roma, 2002.
3. International Obesity Task Force. Incidence, prevalence, and co-morbidity. Available at: "http://www.obesity.chair.ulaval.ca/IOTF.htm, " Accessed March 13, 2002.
4. Deckelbaum R.J., Williams C.L.: Childhood obesity: the health issue. Obes Res., 9 (suppl. 4), 239S-243S, 2001.
5. U.S. Department of Health and Human Services. The surgeon general's call to action to prevent and decrease overweight and obesity 2001. Rockville, MD: US Department of Health and Human Services, Public Health Service, Office of the Surgeon General, 2001.
6. Manson J.E., Willett W.C., Stampfer M.J., Colditz G.A., Hunter D.J., Hankinson S.E., et al.: Body weight and mortality among women. N. Engl. J. Med., 333, 677-685, 1995.
7. Manson J.E., Faich G.A.: Pharmacotherapy for obesity - do the benefits outweigh the risks [editorial]. N. Engl. J. Med., 335, 659-660, 1996.
8. Belisari A., Carruba M.O., Mantovani L.G.: Overweight and obesity: the cost to society and the association with BMI. Value in Health, 5, 168, 2001.
9. National Heart, Lung, and Blood Institute Obesity Education Initiative. The Practical Guide Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Rockville, MD: US Department of Health and Human Services; Public Health Service; National Institutes of Health; National Heart, Lung, and Blood Institute; NIH Publication Number 00-4084, October, 2000.
10. National Institutes of Health. The sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Bethesda, MD: National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program; NIH Publication Number 98-4080. November, 1997.
11. Guidelines Subcommittee of the World Health Organization - International Society of Hypertension. 1999 World Health Organization. International Society of Hypertension Guidelines for the Management of Hypertension. J. Hypertens., 17, 151-183, 1999.
12. Colditz G.A., Willett W.C., Rotnitzky A., Manson J.E.: Weight gain as a risk factor for clinical diabetes mellitus in women. Ann. Intern. Med., 122, 481-486, 1995.
13. Brown CD., Higgins M., Donato K.A., Rohde F.C., Garrison R., Obarzanek E., et al.: Body mass index and the prevalence of hypertension and dyslipidemia. Obes. Res., 8, 605-619, 2000.
14. Williamson D.F., Pamuk E., Thun M., Flanders D., Byers T., Heath C: Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years. Am. J. Epidemiol., 141, 1128-1141, 1995.
15. Tuck M.L., Sowers J., Dornfeld L., Kledzik G., Maxwell M.: The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N. Engl. J. Med., 304, 930-933, 1981.
16. Dattilo A.M., Kris-Etherton P.M.: Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am. J. Clin. Nutr., 56, 320-328, 1992.
17. UK prospective study on maturity onset diabetes. Effect of diet and sulphonylurea, insulin or biguainide therapy on fasting plasma glucose and body weight over a year. A multicentre study. Diabetologia, 24, 404-411, 1983.
18. Bosello O., Armellini F., Zamboni M., Fitchet M.: The benefits of modest weight loss in type 2 diabetes. Int. J. Obes. Relat. Metab. Disord., 21 (suppl 1), S10-S13, 1997.
19. Tuomilehto J., Lindström J., Eriksson J.G., et al., for the Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med., 344, 1343-1350, 2001.
20. U.S. Department of Health and Human Services. Diet and exercise dramatically delay Type 2 diabetes: Diabetes Medication Metformin Also Effective. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Available at: HYPERLINK "http://www.niddk. nih.gov/welcome/releases/8-9-01.htm,"
21. www.nidd-knih.gov/welcome/releases/8-9-01.htm. Accessed March 12, 2002.
22. National Task Force on the Prevention and Treatment of Obesity: Long-term pharmacotherapy in the management of obesity. JAMA, 276, 1907-1915, 1996.
23. Royal College of Physicians of London: Clinical management of overweight and obese patients with particular reference to the use of drugs. London: A report of the Royal College of Physicians of London, December, 1998.
24. Hansen D.L., Toubro S., Stock M.J., MacDonald I.A., Astrup A.: The effect of sibu-tramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int. J. Obes. Relat. Metab. Disord., 23, 1016-1024, 1999.
25. Nisoli E., Carruba M.: An assesssment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes. Rev., 1, 127-139, 2000.
26. Astrup A., Chong E.: Weight loss produced by sibutramine: a meta-analysis. Int. J. Obes. Relat. Metab. Disord., 25 (suppl 2), S104, 2001.
27. Heitmann B.L., Garby L.: Patterns of long-term weight changes in overweight developing Danish men and women aged between 30 and 60 years. Int. J. Obes. Relat. Metab. Disord., 23, 1074-1078, 1999.
28. James W.P.T., Astrup A., Finer N., et al., for the STORM Study Group: Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet, 356, 2119-2125, 2000.
29. Wing R.R., Marcus M.D., Epstein L.H., Salata R.: Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care, 10, 563-566, 1987.
30. Van Gaal L.F., Peiffer F.W.: The importance of obesity in diabetes and its treatment with sibutramine. Int. J. Obes. Relat. Metab. Disord., 25 (suppl 4), S24-S28, 2001.
31. Wauters M., Peiffer F., Gubbels N., Van De Sampel A.M., Corthouts R., DeSchepper A., et al.: Visceral fat decreases after six months treatment with sibutramine in obese subjects. Int. J. Obes. Relat. Metab. Disord., 72, 1997.
32. Wirth A., Krause J.: Long-term weight loss with sibutramine: a randomized controlled trial. JAMA, 286, 1331-1339, 2001.
33. Smith LG., Goulder M.A.: Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J. Fam. Pract, 50, 505-512, 2001.
34. Fanghanel G., Cortinas L., Sanchez-Reyes L., Berber A.: Second phase of double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment crossover. Int. J. Obes. Relat. Metab. Disord., 25, 741-747, 2001.
35. Hansen D., Astrup A., Toubro S., Finer N., Kopelman P., Hilsted J., Rossner S., Saris W., Van Gaal L., Goulder M. for the STORM Stoudy Group: Predictors of weight loss and maintenance during 2 years of teatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance. Int. J. Obes. Relat. Metab. Disord., 25, 496-501, 2001.
36. Gokcel A., Gumurdulu Y., Karakose H., Melek Ertorer E., Tanaci N., BascilTutuncu N., Guvener N.: Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes. Metab., 4, 49-55, 2002.
37. Astrup A., Toubro S.: When, for whom and how to use sibutramine? Int. J. Obes. Relat. Metab. Disord., 25 (suppl 4), S2-S7, 2001.
38. Berube-Parent S., Prud'homme D., St-Pierre S., Doucet E., Tremblay A.: Obesity treatment with a progressive clinical tri-therapy combining sibutramine and a supervised diet-exercise intervention. Int. J. Obes. Relat. Metab. Disord., 25, 1144-1153, 2001.
39. Wadden T.A., Berkowitz R.I., Saryer D.B., Prus-Wisniewski R., Steinberg C: Benefits of lifestile modification in the pharmacologic treatment of obesity: a randomized trial. Arch. Intern. Med., 161, 218-227, 2001.
40. Samsa G.P., Kolotkin R.L., Williams G.R., Nguyen M.H., Mendel CM.: Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomizzed trials of sibutramine vs placebo. Am. J. Manag. Care, 7, 875-883, 2001.
41. Appolinario J.C., Godoy-Matos A., Fontenelle L.F., Carraro L., Cabrai M., Vieira A., Coutinho W.: An oper-label trial of sibutramine in obese patients with binge-eating disorder. J. Clin. Psichiatry, 63, 28-30, 2002.
42. Serrano-Rios M., Melchionda N., Moreno-Carretero E.: Role of sibutramine in the teat-ment of obese Type 2 diabetic patients receiving sulphonylurea therapy. Diabet. Med., 19, 119-124, 2002.
43. Sircar A.R., Kumar A., Lall M.: Clinical evaluation of sibutramine in obese type 2 diabetic patients refractory to dietary management. J. Assoc. Physicians India, 49, 885-888, 2001.
44. Gokcel A., Karakose H., Ertorer E.M., Tanaci N., Tutuncu N.B., Guvener N.: Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care, 24, 1957-1969, 2001.
45. Mooradian A.D.: Obesity: a rational target for managing diabetes mellitus. Growth Horm. IGF Res., 11 (Suppl A), S79-S93, 2001.
46. Dujovne CA., Zavoral J.H., Rowe E., Mendel CM.: Effects of sibutramine on body weight and serum lipids: a double-blind, randomized placebo-controlled study in 322 overweight and obese patients with dyslipidemia. Am. Heart J., 142, 489-497, 2000.
47. McLaughlin T., Abbasi F., Lamendola C, Kim H.S., Reaven G.M.: Metabolic changes following sibutramine-assisted weight loss in obese individuals: role of plasma free fatty acids in the insulin resistence of obesity. Metabolism 50, 819-824, 2001.
48. McLaughlin T., Abbasi F., Kim H.S., Lamendola C., Schaaf P., Reaven G.M.: Relationship between insulin resistance, weight loss, and coronary hearth disease risk in healthy, obese women. Metabolism, 50, 795-800, 2001.
49. Sharma A.M.: Sibutramine in overweight/obese hypertensive patients. Int. J. Obes. Relat. Metab. Disord., Suppl 4, S20-S23, 2001.
50. Sramek J.J., Leibowitz M.T., Weinstein S.P., Rowe E.D., Mendel CM, Levy B., McMahon F.G., Mullican W.S., Toth P.D., Cutler N.R.: Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double blind randomized trial. J. Hum. Hypertens., 16, 13-19, 2002.
51. McMahon F.G., Weinstein S.P., Rowe E., Ernst K.R., Johnson F., Fujiioka K.: Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J. Hum. Hypertens., 16, 5-11, 2002.
52. Federfarma. Data on web site (HYPERLINK "http://www.federfarma.it, "
53. www.federfar-ma.it) accessed on 27-06-2002.